When: Close below $280 on volume (50 SMA break)

Then: Thesis review warranted; stop triggered

HOLD

• Revenue up 11.5%, FCF up 57.7%, ROE 39.7% in Q2 confirmed but already priced at $293.73 (7% below 52-week high, 79% through 52-week range)
• Trailing P/E of 23.8x is the actual delivered number versus forward EPS estimate of $14.15 (trailing $12.36); estimates can be cut
• Four-margin lines compressed simultaneously: gross -69bps, operating -78bps, EBITDA -191bps, net -145bps, plus tax rate jumped 18.9% to 22.0%
• Buyback collapse: $6.28B (2022) → $705M (2023) → $1.5B (2024) → $2.7B (2025) → $26M (Q2 2026) signals management lacks conviction
• Merger faces coordinated opposition: Berkshire Hathaway filed formal motion to deny with $4.5B in Q2 buybacks, seven GOP AGs, shipper trade groups
• Regulatory base case is prolonged STB review with conditions; bear case is outright denial at $250-270
• Technical coil pattern is directionally ambiguous with ATR compressing 7.29 to 6.00 and MACD negative for 11 sessions
• Balance sheet stress: current ratio 0.986, net debt $28.7B, dividend exceeding FCF in 2025
• Trim at $300-305 locks in gains while maintaining 67-75% position exposure to merger upside
• Sentiment score 5/10 with low confidence; retail engagement zero; bullish framing comes from conflicted sell-side analysts

→ vs aggressive: Q2 metrics confirm franchise quality but the market already prices this in; calling for buying at $293.73 near 52-week highs is momentum logic that gets investors buying at tops

→ vs aggressive: Forward EPS differential of $14.15 vs $12.36 trailing is an analyst estimate not delivered earnings; even a 5% cut collapses the bull case

→ vs aggressive: Margin compression across all four lines in same quarter is a pattern not a rounding error; cost structure is starting to bite

→ vs aggressive: Berkshire Hathaway is the largest, most sophisticated, most capitalized opponent with unlimited resources to drag out regulatory process; this is not fringe opposition

→ vs aggressive: The 'put option' from buybacks is overstated: $5-8B buyback on $174B market cap is 3-5% of float, stock would drop 10-15% on denial before any support kicks in

→ vs aggressive: Coil pattern breaks down as often as up; MACD negative for 11 weeks with expanding histogram suggests path of least resistance is not higher

→ vs aggressive: Adding at $293.73 with stop at $268 risks 8.7% of capital on an asset at all-time highs with full valuation and binary regulatory overhang

→ vs neutral: Waiting for confirmation above $294.50 or below $286.40 is not market-average thinking but disciplined risk management to avoid being exit liquidity

HOLD

• Reinforces HOLD with trim discipline at $300-$305 (recommends tightening to $300) and stop at $268
• Scale-in re-engagement zone of $270-$280: one-third at $280, one-third at $275, one-third at $270
• 23.8x trailing earnings multiple offers no margin of safety; forward EPS differential of $14.15 vs trailing $12.36 is forecast, not delivered earnings
• All four margin lines compressed simultaneously on accelerating revenue—signal, not noise
• Tax rate structurally increased from 18.9% to 22.0%
• STB requires higher standard for transcontinental combinations; UNP-NS proposal at $71.5-$85 billion is materially larger than CP-KCS
• BNSF opposition and seven AGs represent credible, well-funded opposition not to be dismissed
• $26 million Q2 2026 buyback more plausibly reflects merger-related cash preservation than insider skepticism
• Absence of retail engagement on $174B institutionally-held name is normal, not bearish
• Institutional positioning, hedge fund flow, and analyst coverage remain constructive to neutral
• Wait for higher-conviction entry: confirmed technical breakout above 10 EMA with MACD histogram positive, or STB procedural ruling

→ vs aggressive: 23.8x trailing multiple prices in delivered results, not forecasts; Q2 beat of 11.5% revenue and 57.7% FCF is already reflected at 79% of 52-week range

→ vs aggressive: All four margin lines compressing on accelerating revenue is late-cycle cost absorption, not a molehill; operating income growing 9.4% masks deteriorating margin profile

→ vs aggressive: $5-$8 billion buyback against $174 billion market cap is 3-5% of float, deployed over quarters—not a put option that catches you on a 10-15% decline

→ vs aggressive: BNSF, 7 AGs, and shipper groups have unlimited Berkshire resources; STB has signaled transcontinental combinations face higher review standard

→ vs conservative: $26 million Q2 2026 buyback collapse reflects merger-related cash preservation ahead of $85 billion obligation, not management skepticism

→ vs conservative: UNP is $174 billion institutionally-held railroad; absence of retail chatter is normal, not bearish signal

→ vs conservative: $270-$280 re-engagement zone may not materialize; patient risk management means waiting for higher-conviction setup, not anchoring to textbook entry